New Study Finds That Stabalized Rice Bran May Help 35 Million Diabetics By Lowering Blood Glucose Levels

El Dorado Hills, CA. February 25, 2002 – NutraStar™ Incorporated OTC BB (NTRA) announced today that a double-blind, cross-over study, which is to be published in the March issue of the Journal of Nutritional Biochemistry, may hold a key for the 35 million Americans who are fighting diabetes, a finding that was recently reported by The Centers For Disease Control. The results of this diabetes study indicate that supplementing the diet with products derived from stabilized rice bran may help lower blood sugar levels in both Type I and Type II diabetics.

“This is a significant finding in view of the short duration of the study,” said Dr. Asaf Qureshi, Principle Researcher. “One out of four diabetics in the 57-subject study lowered their daily dosage of medication by 30%-60%, just by adding special stabilized rice bran derivatives, RiSolubles® or RiceMucil® , to their daily diet. While not all of the subjects were able to reduce their hyperglycemic medications, all of the subjects were able to maintain a lower blood glucose level on these regimens as compared to their respective placebo groups.”

Qureshi and his colleagues at Advanced Medical Research in Madison, Wisconsin found that by consuming 20 grams per day of either RiSolubles® or RiceMucil®, for 60 days, both Type I and Type II diabetics were able to lower their blood sugar levels by 30% and 20% respectively.

In addition, the study also found that these stabilized rice bran derivatives were able to lower total serum cholesterol and total triglycerides between 5% and 15% in subjects with normal cholesterol levels. “Not only did we find a decrease in the blood glucose levels,” said Qureshi, “but we also found a significant effect in lowering triglyceride and apo-lipoprotein B levels in these diabetic patients.”

NutraStar™ is the exclusive world-wide licensee of the rights to U.S. Patent Number 6,126,943, issued on October 16, 2001. The patent is held by The RiceX Company (OTC BB RICX), the exclusive manufacturer of the stabilized rice bran derivatives, which were used in the study. RiceX and NutraStar jointly prosecuted the patent entitled “A Method for Treating Hyperglycemia, Hypoglycemia and Diabetes.”

NutraStar™ Incorporated is emerging as a pioneering, science-based growth company. NutraStar is focused on becoming the world’s leading nutraceutical company through the development and distribution of its proprietary stabilized rice bran “super foods”, natural arthritic relief products for humans and animals and “all natural” cosmeceuticals and beauty aids. The company is headquartered at 1261 Hawk’s Flight Court, El Dorado Hills, California 95762.

Interested persons are encouraged to visit the company’s website at this release contains statements that are forward looking. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission, including the company’s most recent periodic report.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.